PL2968306T3 - Podawanie mononukleotydu nikotynamidu do leczenia zespołu suchego oka - Google Patents

Podawanie mononukleotydu nikotynamidu do leczenia zespołu suchego oka

Info

Publication number
PL2968306T3
PL2968306T3 PL14764546.9T PL14764546T PL2968306T3 PL 2968306 T3 PL2968306 T3 PL 2968306T3 PL 14764546 T PL14764546 T PL 14764546T PL 2968306 T3 PL2968306 T3 PL 2968306T3
Authority
PL
Poland
Prior art keywords
nicotinamid
mononucleotide
administration
treatment
dry eye
Prior art date
Application number
PL14764546.9T
Other languages
English (en)
Inventor
Shin-Ichiro Imai
Rajendra APTE
Original Assignee
Washington University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington University filed Critical Washington University
Publication of PL2968306T3 publication Critical patent/PL2968306T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/20—Animal model comprising regulated expression system
    • A01K2217/206—Animal model comprising tissue-specific expression system, e.g. tissue specific expression of transgene, of Cre recombinase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL14764546.9T 2013-03-15 2014-03-17 Podawanie mononukleotydu nikotynamidu do leczenia zespołu suchego oka PL2968306T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361801188P 2013-03-15 2013-03-15
US201461947387P 2014-03-03 2014-03-03
PCT/US2014/030920 WO2014146044A1 (en) 2013-03-15 2014-03-17 Administration of nicotinamide mononucleotide in the treatment of disease

Publications (1)

Publication Number Publication Date
PL2968306T3 true PL2968306T3 (pl) 2024-01-29

Family

ID=51538175

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14764546.9T PL2968306T3 (pl) 2013-03-15 2014-03-17 Podawanie mononukleotydu nikotynamidu do leczenia zespołu suchego oka

Country Status (5)

Country Link
US (6) US9844561B2 (pl)
EP (2) EP2968306B1 (pl)
ES (1) ES2952032T3 (pl)
PL (1) PL2968306T3 (pl)
WO (1) WO2014146044A1 (pl)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104814974A (zh) * 2015-03-16 2015-08-05 邦泰生物工程(深圳)有限公司 烟酰胺单核苷酸在制备抗衰老药物或保健品的应用
JP2018100222A (ja) * 2015-04-20 2018-06-28 学校法人慶應義塾 角膜損傷の治療剤、改善剤または予防剤
US20180177703A1 (en) * 2015-06-25 2018-06-28 N.V. Perricone Llc Niacinamide Mononucleotide Formulations For Skin Aging
US9855289B2 (en) 2015-08-05 2018-01-02 Metro International Biotech, Llc Nicotinamide mononucleotide derivatives and their uses
GB2542881B (en) 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
WO2018030389A1 (ja) * 2016-08-08 2018-02-15 学校法人 慶應義塾 Nad関連代謝産物の利用
US10898738B2 (en) 2016-09-13 2021-01-26 Megumi Tanaka Visual function printing agent, and method for improving visual functions
US20190328761A1 (en) 2016-12-21 2019-10-31 Newsouth Innovations Pty Limited Methods for enhancing vascular density
US11634690B2 (en) 2017-01-31 2023-04-25 Oriental Yeast Co., Ltd. Agent for accelerating growth of pluripotent stem cells
JP7374585B2 (ja) 2017-02-08 2023-11-07 オリエンタル酵母工業株式会社 皮膚色素沈着抑制剤
JP6920071B2 (ja) 2017-02-16 2021-08-18 ワシントン・ユニバーシティWashington University アディポネクチン分泌向上剤
JP6917239B2 (ja) * 2017-08-03 2021-08-11 旭化成ファーマ株式会社 タンパク質およびその製造方法、タンパク質組成物ならびにそれを用いたnmnの測定方法および測定組成物
JP2020530460A (ja) * 2017-08-10 2020-10-22 ワシントン・ユニバーシティWashington University ニコチンアミドモノヌクレオチドを使用する治療の組成物および方法
JP7210459B2 (ja) * 2017-09-14 2023-01-23 めぐみ 田中 老化防止剤及び老化防止方法
WO2019152416A1 (en) 2018-01-30 2019-08-08 Metro International Biotech, Llc Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof
US20210108242A1 (en) 2018-03-20 2021-04-15 Mitsubishi Corporation Life Sciences Limited Method for producing beta-nmn and composition containing the same
US11814652B2 (en) 2018-03-22 2023-11-14 Oriental Yeast Co., Ltd. Pluripotent stem cell differentiation-promoting agent
EP3794005B1 (en) * 2018-05-15 2025-10-22 Jumpstart Fertility Pty Ltd Inorganic salts of nicotinic acid mononucleotide as anti-aging agents
EP3850954A4 (en) * 2018-09-14 2022-06-08 Megumi Tanaka ANTI-AGEING AGENTS AND PROCESSES
CN109939120B (zh) * 2019-03-01 2020-01-31 北京慧宝源生物技术股份有限公司 含烟酰胺单核苷酸和罗汉果苷的组合物及其应用
US11939348B2 (en) 2019-03-22 2024-03-26 Metro International Biotech, Llc Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide
US10618927B1 (en) 2019-03-22 2020-04-14 Metro International Biotech, Llc Compositions and methods for modulation of nicotinamide adenine dinucleotide
WO2020262497A1 (ja) * 2019-06-25 2020-12-30 千寿製薬株式会社 ニコチンアミドモノヌクレオチド(nmn)およびニコチンアミドリボシド(nr)の新規用途
BR112022002156A2 (pt) * 2019-08-06 2022-06-07 Lianyungang Jinkang Hexin Pharmaceutical Co Ltd Composição farmacêutica para tratamento da febre suína africana e seu uso
FR3108032B1 (fr) 2020-03-12 2024-02-16 Nuvamid Sa Utilisation de NMN pour la prévention et/ou le traitement d’une douleur musculaire, ligamentaire ou tendineuse induite par l’activité physique et compositions correspondantes
FR3108031B1 (fr) 2020-03-12 2024-02-16 Nuvamid Sa Utilisation de NMN pour la prévention et/ou le traitement d’une douleur dorsale et compositions correspondantes
EP4122536A4 (en) * 2020-03-16 2024-04-24 Megumi Tanaka Coenzyme q production promoter and coenzyme q production promoting method
CN115605207A (zh) * 2020-05-14 2023-01-13 葡默药物技术有限公司(Us) 用于经粘膜给药的固体剂型
CN112089706A (zh) * 2020-09-28 2020-12-18 深圳雾件科技有限公司 一种烟酰胺单核苷酸缓释微丸及其制备方法
JP7553335B2 (ja) * 2020-11-30 2024-09-18 日清ファルマ株式会社 β-ニコチンアミドモノヌクレオチド含有製剤
RS65326B1 (sr) 2020-12-18 2024-04-30 Nuvamid Sa Derivati nikotinamid mononukleotida u lečenju i prevenciji bolesti srpastih ćelija
CN112569249A (zh) * 2020-12-29 2021-03-30 中科健康产业集团股份有限公司 一种具有抗衰老作用的番茄红素组合物的制备方法
JP2024503867A (ja) * 2021-01-14 2024-01-29 バイオエナジー ライフ サイエンス,インコーポレイティド 健康な中年集団におけるnad+メタボロームを増加させるための方法及び組成物
CN113133981A (zh) * 2021-04-20 2021-07-20 北京天玺宝科技有限公司 β-烟酰胺单核苷酸口崩片及其制备方法
CA3219033A1 (en) 2021-05-27 2022-12-01 Metro International Biotech, Llc Crystalline solids of nicotinic acid mononucleotide and esters thereof and methods of making and use
JP7696603B2 (ja) * 2021-06-29 2025-06-23 株式会社常磐植物化学研究所 サーチュイン活性化剤
US11571438B1 (en) * 2022-05-23 2023-02-07 Sasan Akhavan Nutraceutical compositions to up-regulate SIRT1 and methods of use
AU2023307487A1 (en) 2022-07-15 2025-01-23 Danstar Ferment Ag Combination of bifidobacterium and fucosylated hmo for use in increasing nmn or nad+
JP2024151469A (ja) * 2023-04-12 2024-10-25 長崎県公立大学法人 エネルギー消費促進による体温上昇用の食品

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
CN1964627B (zh) * 2004-06-04 2011-10-19 华盛顿大学 治疗神经病变的方法和组合物
US8268575B2 (en) 2004-09-20 2012-09-18 Washington University NAD biosynthesis systems
US20070014833A1 (en) 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
EP2805719A1 (en) 2005-03-30 2014-11-26 Glaxosmithkline LLC Nicotinamide riboside and analogues thereof
CA2609549A1 (en) * 2005-05-25 2006-11-30 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
US7737158B2 (en) 2005-10-11 2010-06-15 Washington University Processes for regulating blood glucose in a mammal
CA2676609A1 (en) 2007-01-26 2008-07-31 Washington University Methods and compositions for treating neuropathies
EP2057905A1 (en) 2007-11-12 2009-05-13 TIMA Foundation Composition for moderating Triglyceride and Cholesterol Levels
CN101601679B (zh) 2009-03-17 2011-08-10 中国人民解放军第二军医大学 一种烟酰胺单核苷酸的应用
DE102010030911A1 (de) 2010-07-02 2012-01-05 Kunststoff-Technik Scherer & Trier Gmbh & Co Kg Verfahren zur Herstellung eines Formteils und Formteil
WO2012114204A2 (en) 2011-02-15 2012-08-30 Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto Methods of treating mitochondrial dysfunction
EP2726601B1 (en) 2011-06-29 2018-12-26 The General Hospital Corporation Compositions and methods for enhancing bioenergetic status in female germ cells
EP3345901A3 (en) * 2011-06-29 2018-09-12 President and Fellows of Harvard College Small molecules as antiaging agents

Also Published As

Publication number Publication date
US11793824B2 (en) 2023-10-24
WO2014146044A1 (en) 2014-09-18
US20240009222A1 (en) 2024-01-11
US10258638B2 (en) 2019-04-16
US20160022712A1 (en) 2016-01-28
US9844561B2 (en) 2017-12-19
US10925888B2 (en) 2021-02-23
EP4233878B1 (en) 2025-05-07
EP2968306A1 (en) 2016-01-20
EP4233878A1 (en) 2023-08-30
US20210346413A1 (en) 2021-11-11
US20190224223A1 (en) 2019-07-25
ES2952032T3 (es) 2023-10-26
US20180050054A1 (en) 2018-02-22
US20250049833A1 (en) 2025-02-13
US12150950B2 (en) 2024-11-26
EP2968306B1 (en) 2023-06-07
EP2968306A4 (en) 2016-11-02

Similar Documents

Publication Publication Date Title
IL268987B (en) System for glaucoma treatment
IL260383B (en) Low dose therapeutic treatment
HUE058737T2 (hu) Eljárások arenaviridae vírusok okozta fertõzések kezelésére
HUE061618T2 (hu) Vegyület szemrendellenességek kezelésére
PL3186244T3 (pl) Analogi dioksolanowe urydyny w leczeniu raka
PL3936130T3 (pl) Schemat dawkowania walbenazyny w leczeniu hiperkinetycznych zaburzeń ruchu
EP3620203C0 (en) VASCULAR TREATMENT DEVICES
SG11201600522UA (en) Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
HUE061761T2 (hu) Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében
IL260684B (en) Treatment for modulating gut microbiota
LT3139903T (lt) Vandeninis akių tirpalas ir sausų akių sindromo gydymo būdas
LT3019503T (lt) Policikliniai karbamoilpiridono junginiai ir jų panaudojimas živ infekcijų gydymui
DK3099356T3 (da) Medikamentadministrationsanordning
LT3019499T (lt) Policikliniai karbamoilpiridono junginiai ir jų panaudojimas živ infekcijų gydymui
HUE056006T2 (hu) Kombináció Parkinson-kór kezelésére
DK3380146T3 (da) Medikamentadministrationsanordning
PT2859896T (pt) Composições farmacêuticas para o tratamento de distúrbios musculares
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
ZA201902090B (en) Combination treatments comprising administration of imidazopyrazinones
PT3042669T (pt) Agente antitumoral e potencializador de efeito antitumoral
PT3188599T (pt) Tratamentos médicos baseados em anamorelina
EP2983648A4 (en) COMBINATION THERAPEUTIC NANOPARTICLES
HUE061741T2 (hu) Maszk szemszárazság kezelésére
EP3356472C0 (en) PARTICLE SURFACE TREATMENT
EP2839068A4 (en) Clothes treatment apparatus